- Research article
- Open Access
Aβ impairs nicotinic regulation of inhibitory synaptic transmission and interneuron excitability in prefrontal cortex
© Chen et al.; licensee BioMed Central Ltd. 2013
- Received: 18 September 2012
- Accepted: 4 January 2013
- Published: 17 January 2013
Accumulation of β-amyloid (Aβ) and cholinergic deficiency are two prominent features of Alzheimer’s disease (AD). To understand how Aβ-induced dysfunction of the nicotinic system may contribute to cognitive impairment in AD, we examined the effect of Aβ on nicotinic regulation of synaptic transmission and neuronal excitability in prefrontal cortex (PFC), a brain region critical for cognitive processes.
We found that activation of nicotinic acetylcholine receptors (nAChRs) with nicotine increased the inhibitory postsynaptic currents recorded in PFC pyramidal neurons, which was associated with the nicotine-induced increase in the excitability of PFC layer I GABAergic interneurons. Both effects of nicotine were disrupted by Aβ. However, Aβ did not impair nicotinic regulation of excitatory neurotransmission in PFC interneurons. The nicotinic effect on synaptic inhibition was also lost in transgenic mice with five familial Alzheimer’s disease mutations. Inhibiting PKC attenuated nicotinic regulation of inhibitory, but not excitatory, neurotransmission.
Our study suggests that Aβ selectively impairs nicotinic regulation of inhibitory inputs to PFC pyramidal neurons, which might be due to its interference with PKC activation. Thus, in the PFC circuits of AD, the balance between inhibition and excitation under the control of nAChRs may be disturbed by Aβ.
- Alzheimer’s disease
- Nicotinic acetylcholine receptor
- Prefrontal cortex
- Pyramidal neuron
- Inhibitory postsynaptic current
- Protein kinase C
Aβ plays a critical role in the pathogenesis of Alzheimer’s disease (AD) [1–4]. Earlier studies show that Aβ can cause cell death in cultured neurons  by inducing oxidative stress and disrupting intracellular calcium homeostasis . Recent evidence suggests that the cognitive deficit and memory loss in early stages of AD are due to synaptic failure  and functional changes in the activity of neuronal network . However, the role of Aβ in synaptic dysfunction in AD is far from clear.
In addition to Aβ accumulation, another hallmark of AD is a selective loss of cholinergic neurons in basal forebrain , and the loss of nicotinic acetylcholine receptors (nAChRs) in the hippocampus and cortex [10, 11]. Neuronal nAChR is a pentameric structure formed from α- and β- subunits (α2-α10, β2-β4). nAChRs are distributed in both presynaptic and postsynaptic sites [12, 13], regulating transmitter release, synaptic response and neuronal excitability . Animal studies have found that nAChR activation improves working memory [15, 16], while nAChR antagonist, mecamylamine, impairs attention accuracy or reaction time [17, 18]. Clinical drugs targeting nAChRs improve symptoms in AD patients .
It has been suggested that nAChRs are involved in regulating the integrated circuit activity between interneurons and projection neurons [20, 21]. We hypothesize that Aβ may interrupt nicotinic regulation of inhibitory/excitatory balance at cortical circuits, thus contributing to the loss of cognition and memory in AD. To test this, we examined the effect of nicotine on inhibitory inputs to cortical pyramidal neurons and the excitatory inputs to cortical interneurons, as well as the potential impact of Aβ on the regulatory effects of nAChRs.
Nicotine increases inhibitory neurotransmission in PFC layer V pyramidal neurons through non-α7 nACh receptors
To identify the possible receptor subtypes that mediate the nicotinic effect, we applied nAChR antagonists to PFC slices. As shown in Figure 1D, mecamylamine (MEC, 10 μM), a non-α7 nAChR antagonist, largely blocked the effect of nicotine on sIPSC amplitude (0.4 ± 1.6%, n = 5) and frequency (12.6 ± 4.1%, n = 5). In contrast, in the presence of methyllycaconitine (MLA, 1 μM), an α7 nAChR antagonist, the effect of nicotinic on sIPSC was not significantly changed (amplitude: 41.1 ± 6.9%, frequency: 41.3 ± 3.8%, n = 6). It suggests that the nicotinic effect on sIPSC in layer V PFC pyramidal neurons is mediated by non-α7 nAChRs.
Nicotine boosts the excitability of PFC layer I GABAergic interneurons
To assess whether nicotinic enhancement of sIPSC is due to nAChR-induced increase in the excitability of PFC GABAergic interneurons, we examined the effect of nicotine on action potential firing of interneurons in PFC. Since layer I of neocortex contains exclusively GABAergic interneurons with extensive axonal plexus innervating neurons in deep layers [24–26], we focused our studies on PFC layer I GABAergic interneurons.
We also assessed whether nicotine affects the excitability of deep layer neurons. We found that nicotine did not cause a significant increase in the firing rate or resting potential of layer V fast-spiking interneurons (n = 5). Nicotine also failed to show any significant effect on the firing rate of layer V pyramidal neurons (n = 5).
Aβ attenuates the nicotinic effect on inhibitory transmission in layer V cortical pyramidal neurons
Aβ weakens the nicotinic effect on the excitability of PFC layer I GABAergic interneurons
Aβ does not interfere with nicotinic regulation of excitatory neurotransmission
Why does Aβ differentially affect nicotinic regulation of excitatory vs. inhibitory neurotransmission? One possibility is that distinct nAChR subtypes mediate the nicotinic effect on sEPSC or sIPSC. To test this, we applied specific nAChR antagonists. As shown in Figure 6H, in cells treated with the non-α7 nAChR antagonist MEC (10 μM), nicotine failed to increase sEPSC frequency (2.6 ± 1.6%, n = 4). In contrast, the nicotinic enhancement of sEPSC frequency (97.9 ± 9.9%, n = 4) was intact in cells treated with the α7 nAChR antagonist MLA (1 μM). It suggests that non-α7 nAChRs play a major role in mediating the nicotinic effect on excitatory neurotransmission, which is similar to their major role in mediating the nicotinic effect on inhibitory neurotransmission. Thus, the differential effects of Aβ on nicotinic regulation of sIPSC and sEPSC can not be explained by the nAChRs involved.
PKC is differentially involved in nicotinic regulation of inhibitory vs. excitatory neurotransmission
Having excluded the possibility that nAChR subtypes may contribute to the selective effect of Aβ on nicotinic regulation of inhibitory transmission, we hypothesize that Aβ might interfere with some downstream signaling molecule that is differentially involved in the nicotinic regulation of sIPSC or sEPSC. Our previous studies have found that PKC activation is often impaired by Aβ treatment [30, 32, 33], so we examined the involvement of PKC in nicotinic regulation of sIPSC and sEPSC. PFC slices were pre-incubated with a PKC inhibitor for at least 1 hour, and sIPSC was recorded in layer V pyramidal neurons and sEPSC was recorded in layer I GABAergic interneurons.
Our experiments have shown that, in rat prefrontal cortex, 1) nicotine increased sIPSC in layer V pyramidal neurons and the firing rate in layer I interneurons, both of which were disrupted by Aβ; 2) Aβ did not impair nicotinic regulation of sEPSC in layer I interneurons; 3) PKC inhibitors differentially interfered with nicotinic regulation of excitatory or inhibitory transmission, mimicking the effect of Aβ. These results suggest that Aβ selectively impairs nicotinic regulation of inhibitory inputs to cortical pyramidal neurons, which may involve a PKC-dependent mechanism.
Nicotine often has neuron-specific effects in different networks, which are mediated by different nAChR subtypes [21, 34, 35]. In this study, we have found that nicotine enhances both inhibitory inputs to PFC layer V pyramidal neurons and excitatory inputs to layer I interneurons. In the presence of non-α7 nAChR antagonist MEC, both sIPSC and sEPSC are irresponsive to nicotine, suggesting that α4β2 may mediate these effects of nicotine [20, 36]. Nicotine does not alter the excitability of layer V pyramidal neurons, but significantly increases the firing rate of layer I interneurons, an effect mediated by both α7 and non-α7 nAChRs. Involvement of different nAChRs may also suggest distinct roles of nicotine in regulating neuronal functions. In hippocampal cultures, α7 and α4β2 displayed distinct patterns of expression, with α7 preferentially present on the somatodendrites whereas α4β2 distributed on both the axonal and dendritic compartments . Our results are consistent with the finding that presynaptic α4β2 receptors contribute to neurotransmission [38, 39] and both somatodendritic α7 and presynaptic α4β2 receptors modulate neuronal excitability [12, 40, 41].
Both Aβ accumulation and nicotinic deficits occur in the progression of AD [42, 43]. Aβ peptide may alter nicotinic function in several ways. Direct binding of Aβ1–42 to α7 receptors leads to inhibition of channel open probability  and ionic current [43, 45]. However, several lines of evidence suggest that direct inhibition of nAChRs by Aβ might not be enough to explain Aβ-induced impairment of nicotinic functions. In hippocampal interneurons of transgenic mice overexpressing Aβ, α7 nAChRs are still functioning . Aβ is able to elevate presynaptic calcium levels, which could occlude the enhancing effect of nicotine on calcium-dependent transmitter release . Calcium and PKC have been found to be involved in nicotine-facilitated neurotransmission in interneurons [48, 49]. Our results demonstrate that PKC inhibitor has a similar effect on nicotinic regulation of synaptic transmission as Aβ, suggesting that PKC could be an important mediator in Aβ-induced impairment of nAChR functions in AD. It supports the idea that PKC-related intervention might be promising for AD treatment [50–52].
In this study, we have found that nicotinic regulation of interneuron firing and GABAergic inputs to pyramidal neurons are selectively susceptible to Aβ, while nicotinic regulation of excitatory inputs to interneurons is relatively preserved. It suggests that interneuron-mediated inhibition and its excitability are Aβ targets. It is known that inhibitory terminals of fast-spiking interneurons are better equipped to support prolonged transmitter release at a higher frequency in comparison with pyramidal neurons . Electrical and chemical connections of cortical interneurons promote their synchronous firing, thus interneurons play an important role in coordinating cortical activity [54, 55], which is critical for working memory . The Aβ-induced selective impairment of nicotinic regulation of inhibitory inputs to cortical principal neurons could contribute to the dysfunction of neuronal network and the imbalance of inhibition/excitation, leading to interruption of working memory.
Aβ oligomer was prepared as described previously [28, 57]. Nicotine (Sigma), mecamylamine (Sigma), methyllycaconitine (Tocris), GF109203X (Tocris), myr-PKC20-28 (Calbiochem) were made freshly from stocks.
The transgenic mice that coexpress a total of five FAD mutations [APP K670N/M671L (Swedish) + I716V (Florida) + V717I (London) and PS1 M146L + L286V]  was a generous gift from Dr. William E. Van Nostrand (Stony Brook University). Transgenic males (Hets) were bred with mature females (WT). Genotyping were performed by PCR.
All experiments were performed under the supervision of State University of New York at Buffalo Animal Care Committee. Sprague Dawley rats (3–5 weeks old) were anesthetized with 2-bromo-2-chloro-1,1,1-trifluoroethane (1 ml/100 g) inhalation before decapitation [28, 58]. Brains were quickly removed and sliced (300 μm) with a Leica (Nussloch, Germany) VP1000S Vibratome. Slices were then incubated in artificial CSF (in mM: 130 NaCl, 26 NaHCO3, 3 KCl, 5 MgCl2, 1.25 NaH2PO4, 2 CaCl2, and 10 glucose, pH 7.4, 300 mOsm) bubbled with 95% O2 and 5% CO2.
Patch clamp recordings
Voltage clamp recording of synaptic currents in slices was performed as described previously [33, 59]. The PFC slice was placed in a perfusion chamber attached to the fixed stage of an upright microscope (Olympus Optical, Melville, NY) and submerged in continuously flowing ACSF. For sIPSC recording, patch electrode (3–5 MΩ) was filled with the following solution (in mM): 100 CsCl, 10 HEPES, 1 MgCl2, 1 EGTA, 30 N-methyl-d-glucamine (NMG), 5 MgATP, 0.5 Na2GTP and 12 phosphocreatine, pH 7.2–7.3, 270–280 mOsm. CNQX or DNQX (20 μM) and APV (40 μM) were added to ACSF to block AMPA and NMDA receptors. For sEPSC recording, the internal solution was composed of (in mM): 130 Cs-methanesulfonate, 10 HEPES, 10 CsCl, 4 NaCl, 1 MgCl2, 1 EGTA, 5 NMG, 5 MgATP, and 0.5 Na2GTP and 12 phosphocreatine, pH 7.2, 275–290 mOsm. Bicuculline (10 μM) was added to ACSF to block GABAA receptors. Cells were visualized with a 40x water-immersion lens and illuminated with near infrared (IR) light, and the image was detected with an IR-sensitive CCD camera. A Multiclamp 700A amplifier (Axon Instruments) was used for the recording. Tight seals (2–10 GΩ) from visualized neurons were obtained by applying negative pressure. The membrane was disrupted with additional suction, and the whole-cell configuration was obtained. The access resistances were 13–18 MΩ. The membrane potential was held at −70 mV.
Mini Analysis program (Synaptosoft, Leonia, NJ) was used to analyze synaptic activity. Individual synaptic events with fast onset and exponential decay kinetics were captured with threshold detectors in Mini Analysis software. All quantitative measurements were taken 4–6 min after drug application. Spontaneous IPSC or EPSC recordings of 3 min under each condition were used for obtaining cumulative distribution plots of the amplitudes and inter-event intervals. To measure cell excitability, the whole-cell current-clamp technique [33, 59] was used to record spikes evoked by a 500ms depolarizing current pulse. The amplitude of injected current was adjusted so that 5–7 spikes were elicited in the control ACSF solution. The patch electrode was filled with an internal solution containing (in mM): 60 K2SO4, 60 NMG, 40 HEPES, 4 MgCl2, 0.5 BAPTA, 12 phosphocreatine, 2 Na2ATP and 0.2 Na3GTP, pH 7.2–7.3, 265–270 mOsm. The firing rate of each neuron was averaged from 10 consecutive traces under each condition.
Statistical comparisons of the synaptic currents were made using the Kolmogorov-Smirnov (K-S) test. Experiments with two groups were analyzed statistically using unpaired Student’s t-tests. Experiments with more than two groups were subjected to one-way ANOVA, followed by post hoc Tukey tests.
Numerical values were expressed as mean ± SEM.
This work was supported by NIH grant (AG21923) to Z.Y. and by NSFC grant (81171197) and Bureau of Health of Chongqing Medical Research Grant (2011-1-018) to G-J. C. We would like to thank Xiaoqing Chen for her technical support.
- Esteban JA: Living with the enemy: a physiological role for the beta-amyloid peptide. Trends Neurosci. 2004, 27: 1-3. 10.1016/j.tins.2003.10.008.View ArticlePubMedGoogle Scholar
- Price DL, Sisodia SS: Mutant genes in familial alzheimer’s disease and transgenic models. Annu Rev Neurosci. 1998, 21: 479-505. 10.1146/annurev.neuro.21.1.479.View ArticlePubMedGoogle Scholar
- Selkoe DJ: Alzheimer’s disease: genes, proteins, and therapy. Physiol Rev. 2001, 81: 741-766.PubMedGoogle Scholar
- Tanzi RE, Bertram L: Twenty years of the alzheimer’s disease amyloid hypothesis: a genetic perspective. Cell. 2005, 120: 545-555. 10.1016/j.cell.2005.02.008.View ArticlePubMedGoogle Scholar
- Yankner BA, Duffy LK, Kirschner DA: Neurotrophic and neurotoxic effects of amyloid beta protein: reversal by tachykinin neuropeptides. Science. 1990, 250: 279-282. 10.1126/science.2218531.View ArticlePubMedGoogle Scholar
- Mattson MP: Cellular actions of beta-amyloid precursor protein and its soluble and fibrillogenic derivatives. Physiol Rev. 1997, 77: 1081-1132.PubMedGoogle Scholar
- Selkoe DJ: Alzheimer’s disease is a synaptic failure. Science. 2002, 298: 789-791. 10.1126/science.1074069.View ArticlePubMedGoogle Scholar
- Palop JJ, Chin J, Mucke L: A network dysfunction perspective on neurodegenerative diseases. Nature. 2006, 443: 768-773. 10.1038/nature05289.View ArticlePubMedGoogle Scholar
- Bartus RT, Dean RL, Beer B, Lippa AS: The cholinergic hypothesis of geriatric memory dysfunction. Science. 1982, 217: 408-414. 10.1126/science.7046051.View ArticlePubMedGoogle Scholar
- Paterson D, Nordberg A: Neuronal nicotinic receptors in the human brain. Prog Neurobiol. 2000, 61: 75-111. 10.1016/S0301-0082(99)00045-3.View ArticlePubMedGoogle Scholar
- Perry E, Martin-Ruiz C, Lee M, Griffiths M, Johnson M, Piggott M, Haroutunian V, Buxbaum JD, Nasland J, Davis K, Gotti C, Clementi F, Tzartos S, Cohen O, Soreq H, Jaros E, Perry R, Ballard C, McKeith I, Court J: Nicotinic receptor subtypes in human brain ageing, Alzheimer and lewy body diseases. Eur J Pharmacol. 2000, 393: 215-222. 10.1016/S0014-2999(00)00064-9.View ArticlePubMedGoogle Scholar
- Lena C, Changeux JP, Mulle C: Evidence for “preterminal” nicotinic receptors on GABAergic axons in the rat interpeduncular nucleus. J Neurosci. 1993, 13: 2680-2688.PubMedGoogle Scholar
- Zarei MM, Radcliffe KA, Chen D, Patrick JW, Dani JA: Distributions of nicotinic acetylcholine receptor alpha7 and beta2 subunits on cultured hippocampal neurons. Neuroscience. 1999, 88: 755-764. 10.1016/S0306-4522(98)00246-2.View ArticlePubMedGoogle Scholar
- Dani JA, Bertrand D: Nicotinic acetylcholine receptors and nicotinic cholinergic mechanisms of the central nervous system. Annu Rev Pharmacol Toxicol. 2007, 47: 699-729. 10.1146/annurev.pharmtox.47.120505.105214.View ArticlePubMedGoogle Scholar
- Levin ED, McClernon FJ, Rezvani AH: Nicotinic effects on cognitive function: behavioral characterization, pharmacological specification, and anatomic localization. Psychopharmacology (Berl). 2006, 184: 523-539. 10.1007/s00213-005-0164-7.View ArticleGoogle Scholar
- Nott A, Levin ED: Dorsal hippocampal alpha7 and alpha4beta2 nicotinic receptors and memory. Brain Res. 2006, 1081: 72-78. 10.1016/j.brainres.2006.01.052.View ArticlePubMedGoogle Scholar
- Grottick AJ, Higgins GA: Effect of subtype selective nicotinic compounds on attention as assessed by the five-choice serial reaction time task. Behav Brain Res. 2000, 117: 197-208. 10.1016/S0166-4328(00)00305-3.View ArticlePubMedGoogle Scholar
- Mirza NR, Stolerman IP: Nicotine enhances sustained attention in the rat under specific task conditions. Psychopharmacology (Berl). 1998, 138: 266-274. 10.1007/s002130050671.View ArticleGoogle Scholar
- Wilkinson DG, Francis PT, Schwam E, Payne-Parrish J: Cholinesterase inhibitors used in the treatment of Alzheimer’s disease: the relationship between pharmacological effects and clinical efficacy. Drugs Aging. 2004, 21: 453-478. 10.2165/00002512-200421070-00004.View ArticlePubMedGoogle Scholar
- Alkondon M, Pereira EF, Eisenberg HM, Albuquerque EX: Nicotinic receptor activation in human cerebral cortical interneurons: a mechanism for inhibition and disinhibition of neuronal networks. J Neurosci. 2000, 20: 66-75.PubMedGoogle Scholar
- Mansvelder HD, Keath JR, McGehee DS: Synaptic mechanisms underlie nicotine-induced excitability of brain reward areas. Neuron. 2002, 33: 905-919. 10.1016/S0896-6273(02)00625-6.View ArticlePubMedGoogle Scholar
- Lambe EK, Picciotto MR, Aghajanian GK: Nicotine induces glutamate release from thalamocortical terminals in prefrontal cortex. Neuropsychopharmacology. 2003, 28: 216-225. 10.1038/sj.npp.1300032.View ArticlePubMedGoogle Scholar
- Ohnishi M, Katsuki H, Takagi M, Kume T, Akaike A: Long-term treatment with nicotine suppresses neurotoxicity of, and microglial activation by, thrombin in cortico-striatal slice cultures. Eur J Pharmacol. 2009, 602: 288-293. 10.1016/j.ejphar.2008.11.041.View ArticlePubMedGoogle Scholar
- Chu Z, Galarreta M, Hestrin S: Synaptic interactions of late-spiking neocortical neurons in layer 1. J Neurosci. 2003, 23: 96-102.PubMedGoogle Scholar
- Zhu Y, Zhu JJ: Rapid arrival and integration of ascending sensory information in layer 1 nonpyramidal neurons and tuft dendrites of layer 5 pyramidal neurons of the neocortex. J Neurosci. 2004, 24: 1272-1279. 10.1523/JNEUROSCI.4805-03.2004.View ArticlePubMedGoogle Scholar
- Zhou FM, Hablitz JJ: Layer I neurons of rat neocortex. I. Action potential and repetitive firing properties. J Neurophysiol. 1996, 76: 651-667.PubMedGoogle Scholar
- Tu B, Gu Z, Shen JX, Lamb PW, Yakel JL: Characterization of a nicotine-sensitive neuronal population in rat entorhinal cortex. J Neurosci. 2009, 29: 10436-10448. 10.1523/JNEUROSCI.2580-09.2009.PubMed CentralView ArticlePubMedGoogle Scholar
- Gu Z, Liu W, Yan Z: β-amyloid impairs AMPA receptor trafficking and function by reducing CaMKII synaptic distribution. J Biol Chem. 2009, 284: 10639-10649. 10.1074/jbc.M806508200.PubMed CentralView ArticlePubMedGoogle Scholar
- Gu Z, Yakel JL: Timing-dependent septal cholinergic induction of dynamic hippocampal synaptic plasticity. Neuron. 2011, 71: 155-165. 10.1016/j.neuron.2011.04.026.PubMed CentralView ArticlePubMedGoogle Scholar
- Liu W, Dou F, Feng J, Yan Z: RACK1 is involved in β-amyloid impairment of muscarinic regulation of GABAergic transmission. Neurobiol Aging. 2011, 32: 1818-1826. 10.1016/j.neurobiolaging.2009.10.017.PubMed CentralView ArticlePubMedGoogle Scholar
- Oakley H, Cole SL, Logan S, Maus E, Shao P, Craft J, Guillozet-Bongaarts A, Ohno M, Disterhoft J, Van Eldik L, Berry R, Vassar R: Intraneuronal beta-amyloid aggregates, neurodegeneration, and neuron loss in transgenic mice with five familial Alzheimer’s disease mutations: potential factors in amyloid plaque formation. J Neurosci. 2006, 26: 10129-10140. 10.1523/JNEUROSCI.1202-06.2006.View ArticlePubMedGoogle Scholar
- Tyszkiewicz JP, Yan Z: β-amyloid peptides impair PKC-dependent functions of metabotropic glutamate receptors in prefrontal cortical neurons. J Neurophysiology. 2005, 93: 3102-3111. 10.1152/jn.00939.2004.View ArticlePubMedGoogle Scholar
- Zhong P, Gu Z, Wang X, Jiang H, Feng J, Yan Z: Impaired modulation of GABAergic transmission by muscarinic receptors in a mouse transgenic model of Alzheimer’s disease. J Biol Chem. 2003, 278: 26888-26896. 10.1074/jbc.M302789200.View ArticlePubMedGoogle Scholar
- Frazier CJ, Rollins YD, Breese CR, Leonard S, Freedman R, Dunwiddie TV: Acetylcholine activates an alpha-bungarotoxin-sensitive nicotinic current in rat hippocampal interneurons, but not pyramidal cells. J Neurosci. 1998, 18: 1187-1195.PubMedGoogle Scholar
- Zhang H, Sulzer D: Frequency-dependent modulation of dopamine release by nicotine. Nat Neurosci. 2004, 7: 581-582. 10.1038/nn1243.View ArticlePubMedGoogle Scholar
- Couey JJ, Meredith RM, Spijker S, Poorthuis RB, Smit AB, Brussaard AB, Mansvelder HD: Distributed network actions by nicotine increase the threshold for spike-timing-dependent plasticity in prefrontal cortex. Neuron. 2007, 54: 73-87. 10.1016/j.neuron.2007.03.006.View ArticlePubMedGoogle Scholar
- Xu J, Zhu Y, Heinemann SF: Identification of sequence motifs that target neuronal nicotinic receptors to dendrites and axons. J Neurosci. 2006, 26: 9780-9793. 10.1523/JNEUROSCI.0840-06.2006.View ArticlePubMedGoogle Scholar
- Sher E, Chen Y, Sharples TJ, Broad LM, Benedetti G, Zwart R, McPhie GI, Pearson KH, Baldwinson T, De Filippi G: Physiological roles of neuronal nicotinic receptor subtypes: new insights on the nicotinic modulation of neurotransmitter release, synaptic transmission and plasticity. Curr Top Med Chem. 2004, 4: 283-297. 10.2174/1568026043451393.View ArticlePubMedGoogle Scholar
- Wonnacott S: Presynaptic nicotinic ACh receptors. Trends Neurosci. 1997, 20: 92-98. 10.1016/S0166-2236(96)10073-4.View ArticlePubMedGoogle Scholar
- Alkondon M, Pereira EF, Barbosa CT, Albuquerque EX: Neuronal nicotinic acetylcholine receptor activation modulates gamma-aminobutyric acid release from CA1 neurons of rat hippocampal slices. J Pharmacol Exp Ther. 1997, 283: 1396-1411.PubMedGoogle Scholar
- Mameli-Engvall M, Evrard A, Pons S, Maskos U, Svensson TH, Changeux JP, Faure P: Hierarchical control of dopamine neuron-firing patterns by nicotinic receptors. Neuron. 2006, 50: 911-921. 10.1016/j.neuron.2006.05.007.View ArticlePubMedGoogle Scholar
- Dineley KT: Beta-amyloid peptide–nicotinic acetylcholine receptor interaction: the two faces of health and disease. Front Biosci. 2007, 12: 5030-5038. 10.2741/2445.View ArticlePubMedGoogle Scholar
- Oddo S, LaFerla FM: The role of nicotinic acetylcholine receptors in Alzheimer’s disease. J Physiol Paris. 2006, 99: 172-179. 10.1016/j.jphysparis.2005.12.080.View ArticlePubMedGoogle Scholar
- Pettit DL, Shao Z, Yakel JL: Beta-Amyloid(1–42) peptide directly modulates nicotinic receptors in the rat hippocampal slice. J Neurosci. 2001, 21: RC120-PubMedGoogle Scholar
- Liu Q, Kawai H, Berg DK: Beta -amyloid peptide blocks the response of alpha 7-containing nicotinic receptors on hippocampal neurons. Proc Natl Acad Sci U S A. 2001, 98: 4734-4739. 10.1073/pnas.081553598.PubMed CentralView ArticlePubMedGoogle Scholar
- Spencer JP, Weil A, Hill K, Hussain I, Richardson JC, Cusdin FS, Chen YH, Randall AD: Transgenic mice over-expressing human beta-amyloid have functional nicotinic alpha 7 receptors. Neuroscience. 2006, 137: 795-805. 10.1016/j.neuroscience.2005.10.007.View ArticlePubMedGoogle Scholar
- Dougherty JJ, Wu J, Nichols RA: Beta-amyloid regulation of presynaptic nicotinic receptors in rat hippocampus and neocortex. J Neurosci. 2003, 23: 6740-6747.PubMedGoogle Scholar
- Klein RC, Yakel JL: Paired-pulse potentiation of alpha7-containing nAChRs in rat hippocampal CA1 stratum radiatum interneurones. J Physiol. 2005, 568: 881-889. 10.1113/jphysiol.2005.096081.PubMed CentralView ArticlePubMedGoogle Scholar
- Wanaverbecq N, Semyanov A, Pavlov I, Walker MC, Kullmann DM: Cholinergic axons modulate GABAergic signaling among hippocampal interneurons via postsynaptic alpha 7 nicotinic receptors. J Neurosci. 2007, 27: 5683-5693. 10.1523/JNEUROSCI.1732-07.2007.PubMed CentralView ArticlePubMedGoogle Scholar
- Alkon DL, Sun MK, Nelson TJ: PKC signaling deficits: a mechanistic hypothesis for the origins of Alzheimer’s disease. Trends Pharmacol Sci. 2007, 28: 51-60. 10.1016/j.tips.2006.12.002.View ArticlePubMedGoogle Scholar
- Sun MK, Alkon DL: Bryostatin-1: pharmacology and therapeutic potential as a CNS drug. CNS Drug Rev. 2006, 12: 1-8. 10.1111/j.1527-3458.2006.00001.x.View ArticlePubMedGoogle Scholar
- Youdim MB, Weinstock M: Molecular basis of neuroprotective activities of rasagiline and the anti-Alzheimer drug TV3326 [(N-propargyl-(3R)aminoindan-5-YL)-ethyl methyl carbamate]. Cell Mol Neurobiol. 2001, 21: 555-573. 10.1023/A:1015131516649.View ArticlePubMedGoogle Scholar
- Galarreta M, Hestrin S: Frequency-dependent synaptic depression and the balance of excitation and inhibition in the neocortex. Nat Neurosci. 1998, 1: 587-594. 10.1038/2882.View ArticlePubMedGoogle Scholar
- Galarreta M, Hestrin S: A network of fast-spiking cells in the neocortex connected by electrical synapses. Nature. 1999, 402: 72-75. 10.1038/47029.View ArticlePubMedGoogle Scholar
- Whittington MA, Traub RD: Interneuron diversity series: inhibitory interneurons and network oscillations in vitro. Trends Neurosci. 2003, 26: 676-682. 10.1016/j.tins.2003.09.016.View ArticlePubMedGoogle Scholar
- Howard MW, Rizzuto DS, Caplan JB, Madsen JR, Lisman J, Aschenbrenner-Scheibe R, Schulze-Bonhage A, Kahana MJ: Gamma oscillations correlate with working memory load in humans. Cereb Cortex. 2003, 13: 1369-1374. 10.1093/cercor/bhg084.View ArticlePubMedGoogle Scholar
- Dahlgren KN, Manelli AM, Stine WB, Baker LK, Krafft GA, LaDu MJ: Oligomeric and fibrillar species of amyloid-beta peptides differentially affect neuronal viability. J Biol Chem. 2002, 277: 32046-32053. 10.1074/jbc.M201750200.View ArticlePubMedGoogle Scholar
- Feng J, Cai X, Zhao J, Yan Z: Serotonin receptors modulate GABA(A) receptor channels through activation of anchored protein kinase C in prefrontal cortical neurons. J Neurosci. 2001, 21: 6502-6511.PubMedGoogle Scholar
- Chen G, Kittler JT, Moss SJ, Yan Z: Dopamine D3 receptors regulate GABAA receptor function through a phospho-dependent endocytosis mechanism in nucleus accumbens. J Neurosci. 2006, 26: 2513-2521. 10.1523/JNEUROSCI.4712-05.2006.View ArticlePubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.